Detalles de la búsqueda
1.
Cellular therapy in lymphoma.
Hematol Oncol;
2023 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382086
2.
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
JCO Oncol Pract;
19(3): e407-e416, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36508702
3.
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
Cancers (Basel);
15(22)2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001703
4.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Cancers (Basel);
15(17)2023 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37686611
5.
Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands.
Blood Cancer J;
14(1): 3, 2024 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38177115
6.
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.
Blood Adv;
7(21): 6710-6716, 2023 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37639324
Resultados
1 -
6
de 6
1
Próxima >
>>